Literature DB >> 18617409

Is the G2019S LRRK2 mutation common in all southern European populations?

Spiridon Papapetropoulos1, Nikhil Adi, Lina Shehadeh, Nanette Bishopric, Carlos Singer, Andreas A Argyriou, Elizabeth Chroni.   

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, especially the G2019S mutation, have been identified as a common cause of Parkinson's disease in southern European and other Mediterranean populations (Iberians, Ashkenazi Jews and North African Arabs). Owing to the geographic and historic vicinity of Greece with areas of high prevalence of LRRK2 mutations we studied the frequency of the G2019S mutation in a well characterized cohort of familial and sporadic Parkinson's disease patients of Greek origin from mainland Greece. The prevalence of the LRRK2 R1441C mutation and the G2385R Asian polymorphism was also determined. We identified no patients with any of the studied mutations/polymorphisms. Very low prevalence of the LRRK2 G2019S mutation has been reported in other southern European populations. LRRK2 mutations appear to be limited in certain populations and differing ancestry and founder effects may explain the reported variability. Accurate estimations of the frequency and penetrance of different LRRK2 mutations are essential for correct and cost-efficient use of genetic testing and proper genetic counseling of patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617409     DOI: 10.1016/j.jocn.2007.08.013

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

2.  Association between G2385R and R1628P polymorphism of LRRK2 gene and sporadic Parkinson's disease in a Han-Chinese population in south-eastern China.

Authors:  Jiangping Cai; Yi Lin; Wanjin Chen; Qifang Lin; Bin Cai; Ning Wang; Weihong Zheng
Journal:  Neurol Sci       Date:  2013-04-30       Impact factor: 3.307

3.  LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity.

Authors:  A Gorostidi; J Ruiz-Martínez; A Lopez de Munain; A Alzualde; J F Martí Massó
Journal:  Neurogenetics       Date:  2008-11-20       Impact factor: 2.660

4.  Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.

Authors:  Katerina Melachroinou; Emmanouela Leandrou; Polytimi-Eleni Valkimadi; Anna Memou; Georgios Hadjigeorgiou; Leonidas Stefanis; Hardy J Rideout
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

5.  Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease.

Authors:  Njideka U Okubadejo; Mie Rizig; Oluwadamilola O Ojo; Hallgeir Jonvik; Olajumoke Oshinaike; Emmeline Brown; Henry Houlden
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

Review 6.  The Role of LRRK2 in Neurodegeneration of Parkinson Disease.

Authors:  Qin Rui; Haibo Ni; Di Li; Rong Gao; Gang Chen
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.